Gilteritinib is an inhibitor that targets FLT3. It’s meant for AML patients who’ve relapsed or are resistant after other treatments and have FLT3 mutations. It blocks the FLT3 kinase to stop the growth of cancer cells.
The stuff comes in 40 mg tablet form with a film coating. You take 120 mg a day. It’s meant to be taken on the mouth.
It comes in bottles with 90 pills inside. This med is for AML patients who haven’t worked with or who’ve come back after previous treatments.
